Biotech

All Articles

Gilead pays J&ampJ $320M to exit licensing bargain for seladelpar

.Along With Gilead Sciences on the verge of an FDA selection for its own liver disease medicine sela...

' All hands on deck' at Lilly as peers target obesity market

.CEO David Ricks can easily find the business setting up tents at basecamp responsible for Eli Lilly...

Entero laying off personnel, moving out of workplace and also pausing R&ampD

.Mattress Liquidators has actually turned Entero Rehabs white colored as a slab. The collector purch...

Exelixis goes down ADC after deciding it is actually no suit for Tivdak

.Exelixis is giving up on its own cells element (TF)- targeting antibody-drug conjugate after wrappi...

Relay dislikes SHP2 inhibitor after Genentech leaves

.3 weeks after Roche's Genentech system ignored an SHP2 prevention treaty, Relay Therapy has actuall...

Stoke's Dravet disorder med launched of partial clinical grip

.Stoke Therapies' Dravet disorder drug has been actually devoid of a predisposed grip, getting rid o...

Fierce Biotech's Gabrielle Masson shows Brutal 15 at NYSE

.Ferocious Biotech Partner Publisher Gabrielle Masson provided the 2024 lesson of Intense 15 victors...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has axed its once-monthly twin GLP-1/ GIP receptor agonist, ending (PDF) growth of a m...

Daiichi pays out Merck $170M to form lung cancer cells T-cell engager pact

.Merck &amp Co. has quickly gotten back a few of the expenses of its own Weapon Therapeutics purchas...

BioMarin halts preclinical gene treatment for heart disease

.After BioMarin conducted a spring tidy of its own pipeline in April, the company has made a decisio...